Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial

American Heart Journal

Volumn 166, Issue 3, 2013, Pages

  Lincoff, A Michael ^a   Tardif, Jean Claude ^b   Neal, Bruce ^c   Nicholls, Stephen J ^d   Rydén, Lars ^e   Schwartz, Gregory G ^f   Malmberg, Klas ^e,g   Buse, John B ^h   Henry, Robert R ⁱ   Wedel, Hans ^j   Weichert, Arlette ^g   Cannata, Ruth ^a   Grobbee, Diederick E ^k  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALEGLITAZAR; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; SULFONYLUREA;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EVALUATION; FEMALE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT;

EID: 84883790112     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.05.013     Document Type: Article

References (39)

1. International Diabetes Federation 2011 Global burden: prevalence and projections, 2011 and 2030 2011
2. S. Ahmed, C. Cannon, and S. Murphy Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial Eur Heart J 27 2006 2323 2329
3. D. Bhatt, K. Eagle, and E. Ohman Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis J Am Med Assoc 304 12 2010 1350 1357
4. H. Calhoun, D. Betteridge, and P. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
5. P. Gaede, P. Vedel, and H. Parving Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study Lancet 353 1999 617 622
6. Action to Control Cardiovascular Risk in Diabetes Study Group H. Gerstein, M. Miller, and R. Byington Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 24 2008 2545 2559
7. ADVANCE Collaborative Group A. Patel, S. MacMahon, and J. Chalmers Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 24 2008 2560 2572
8. UK Prospective Diabetes Study (UKPDS) Group, R. Turner, R. Holman, and C. Cull Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
9. K.-T. Khaw, N. Wareham, and R. Luben Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) Br Med J 322 2001 15 18
10. B. Staels, and J.C. Fruchart Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 54 2005 2460 2470
11. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106 1118
12. M. Frick, O. Elo, and K. Haapa Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 20 1987 1237 1245
13. H. Rubins, S. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 6 1999 410 418
14. A. Keech, R. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
15. ACCORD Study Group H. Ginsberg, M. Elam, and L. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 2010
16. M. Jun, C. Foote, and J. Lv Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
17. J. Mychaleckyj, T. Craven, and U. Nayak Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants Diabetes Care 35 5 2012 1008 1014
18. S. Singh, Y. Loke, and C. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis J Am Med Assoc 298 10 2007 1189 1195
19. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
20. J.A. Dormandy, B. Charbonnel, and D.J.A. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Sutdy (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
21. A. Lincoff, K. Wolski, and S. Nicholls Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials J Am Med Assoc 298 10 2007 1180 1188
22. T. Mazzone, P.M. Meyer, and S.B. Feinsein Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes; a randomized trial J Am Med Assoc 296 2006 2572 2581
23. S. Nissen, S. Nicholls, and K. Wolski Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial J Am Med Assoc 299 13 2008 1561 1573
24. J. Lewis, A. Ferrara, and T. Peng Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 4 2011 916 922
25. L. Azoulay, H. Yin, and K. Filion The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study Br Med J 344 2012 1
26. E. Erdmann, E. Song, and R. Spanheimer Pioglitazone and bladder malignancy during observational follow-up of proactive: 6-year update American Diabetes Association 72nd Scientific Sessions. Philadelphia, PA 2012
27. Lewis J, Strom B, Bilker W, et al. Cohort study of pioglitazone and bladder cancer in patients with diabetes fourth interim analysis (8-year), report; 2012 5/30/2012.
28. R.B. Goldberg, D.M. Kendall, and M.A. Deeg A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 2005 1547 1554
29. S.E. Nissen, K. Wolski, and E.J. Topol Effect of muraglitazar on death and major adverse cardiovascular events inpatients with type 2 diabetes mellitus J Am Med Assoc 294 2005 2581 2586
30. AstraZeneca AstraZeneca discontinues development of Galida (tesaglitazar) 2006 AstraZeneca
31. A. Hsiao, D.S. Worrall, and J.M. Olefsky Variance-modeled posterior inference of microarrray data: detecting gene-expression changes in 3T3-L1 adipocytes Bioinformatics 20 2004 3108 3127
32. M. Dietz, P. Mohr, and B. Kuhn Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors ChemMedChem 7 6 2012 1101 1111
33. R. Deehan, P. Maerz-Weiss, and N. Catlett Comparative transcriptional network modeling of three PPAR-a/c co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes PLoS One 7 4 2012 35012
34. R. Henry, A. Lincoff, and S. Mudaliar Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study Lancet 374 2009 126 135
35. M. Herz, F. Gaspari, and N. Perico Effects of high dose aleglitazar on renal function in patients with type 2 diabetes Int J Cardiol 151 2011 136 142
36. L. Ruilope, M. Hanefeld, and A. Lincoff Effects of aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes (ABSTR) J Am Soc Nephrol 23 2012 SA-PO 1115
37. A. Lichtenstein, L. Appel, and M. Brands Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee Circulation 114 2006 82 96
38. K. Thygesen, J. Alpert, and H. White Joint ESC/AACF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction J Am Coll Cardiol 50 22 2007 2173 2195
39. FDA Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes (CDER) CfDEaR 2008